Edesa Biotech, Inc. at its AGM held on May 23, 2023, Kathi Niffenegger, the Chief Financial Officer of the Company, notified the Company of her intention to retire from her position and responsibilities as Chief Financial Officer effective July 15, 2023. Ms. Niffenegger will continue to be employed by the Company as an advisor and remain on the board of directors of the Company's wholly owned U.S. subsidiary. Ms. Niffenegger's decision to retire did not result from a disagreement with the Company or any of its officers or other directors on any matter relating to the operations, policies or practices of the Company.

The Company has succession plans in place for the role of Chief Financial Officer, and anticipates naming a successor to fill Ms. Niffenegger's executive position prior to July 15, 2023.